New York Blood Center National Cord Blood Program
Recruitment status was Recruiting
Umbilical cord blood is used as a source of hematopoietic stem cells for bone marrow reconstition in patients who would be potential candidates for a bone marrow transplant from an unrelated marrow donor. The outcome of transplantation is obtained to assess cord blood myeloid and platelet engraftment, transplant related mortality, overall survival, graft vs. host disease and, for patients with leukemia, lymphoma or myelodysplasia, relapse.
Severe Aplastic Anemia
Procedure: Umbilical Cord Blood Hematopoietic Stem Cell Transplantation
Procedure: Umbilical Cord Blood Transplantation
|Study Design:||Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||New York Blood Center National Cord Blood Program|
- Treatment Related Mortality
- Graft vs. Host Disease
|Study Start Date:||February 1993|
Umbilical cord blood donated to the New York Blood Center’s National Cord Blood Program is collect, tested, processed, cryoprotected and frozen in liquid nitrogen for possible future transplantation to anyone who needs it. The Program has operated under a FDA IND exemption since 1996 and is licensed as a tissue bank by the New York State Department of Health.
Candidates for transplant are patients who disease requires bone marrow transplantation but who do not have a suitable related bone marrow donor. Most patients are those with high risk of refractory leukemia, lymphoma, myelodysplasia, severe aplastic anemia and certain genetic hematologic, immunologic and metabolic diseases.
Patients are treated at bone marrow transplant centers in the United States and in other countries with active marrow transplant programs. Because the NYBC Program operates under IND, patients must sign an informed consent for cord blood transplantation.
Transplant centers report on the transplant procedure (including immediate complications) and on transplant outcome at 3, 6 and 12 months post-transplant and annually thereafter. Data report to the New York Blood Center includes information about the patient’s disease and pre-transplant conditioning regimen and post-transplant endpoints, primarily myeloid and platelet engraftment, transplant related mortality, overall survival, acute and chronic graft vs. host disease, relapse and other post-transplant complications such as infectious disease. The outcome data is used to assess safety and efficacy and will be used to apply for a license from the FDA.
|Contact: Pablo Rubinstein, M.D.||firstname.lastname@example.org|
|Contact: Cladd E Stevens, M.D.||email@example.com|
|United States, New York|
|New York Blood Center||Recruiting|
|New York, New York, United States, 10021|
|Contact: Pablo Rubinstein, M.D. 212-570-3230 firstname.lastname@example.org|
|Contact: Cladd E Stevens, M.D. 212-570-3230 email@example.com|
|Principal Investigator: Pablo Rubinstein, M.D.|
|Principal Investigator:||Pablo Rubinstein, M.D.||New York Blood Center|